What is new on the horizon for the biologics world: New kids of the block - WAO state of art - PubMed
3 hours ago
- #Allergic diseases
- #Type 2 inflammation
- #Biologics
- Advances in understanding type 2 inflammation have led to new biologics and small molecules for allergic diseases.
- New therapies target cytokines, receptors, and intracellular pathways to improve disease management and long-term outcomes.
- The WAO Biologics Therapies Committee reviewed monoclonal antibodies, nanobody-based agents, kinase inhibitors, and small molecules.
- Biologics targeting IL-4, IL-5, IL-13, IL-31, TSLP, and IgE are expanding treatment options for allergic disorders.
- Innovations like Fc-engineered antibodies, bispecific antibodies, and nanobody platforms enhance efficacy and tissue penetration.
- Novel intracellular inhibitors (JAK, SYK, STAT6 degraders) show promise as oral alternatives to injectable therapies.
- Clinical trials report high efficacy and favorable safety, but variability exists across diseases and endotypes.
- Pediatric data are limited, and long-term safety and cost-effectiveness need further evaluation.
- Emerging biologics and small molecules are transforming allergic disease treatment with personalized interventions.
- Future research should focus on long-term safety and standardized approaches for clinical integration.